Travere Therapeutics (TVTX) Stock Insights

TVTX price $50.45 -0.43 -0.85%

Ticker
TVTX
Price
$50.45
Change
-0.43 -0.85%
Market cap ?
$4.76B
P/E ?
-111.29
Forward P/E ?
16.34
Dividend yield ?
0.00%
Beta ?
1.14
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
54
Value
26
Quality
41
Growth
96

Stocklytics score rationale: value 26, quality 41, growth 96.

Financials

2016201720182019202020212022202320242025
133591000154937000164246000175338000198321000131836000109460000145238000233175000490728000

Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function…

Fair value

TVTX fair value $73.86. Price $50.45. Price is 32% below fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 118.66M. Growth 20.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 10.58% (beta 1.1). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 94.26M. Net debt 235.70M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the median P/E of the company's industry. That median uses listed stocks worth at least $10 billion with a positive P/E of 100 or below, and the industry needs at least eight of them. Otherwise the sector median is used when that group also has at least eight, then the market median of those large companies. The multiple used is the lower of that median and 1.25 times the stock's own 10-year median P/E, then kept between 8 and 30. If the stock has no 10-year median, the peer median is kept between 8 and 30. Fair value is the average of the cash-flow value and the earnings value when both exist. Card and credit companies use the earnings value only, because changes in customer receivables distort free cash flow. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Compare TVTX

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-02—-0.05—198.25M
2026-08-04-0.37-0.13169.58M157.27M
2026-05-04-0.39-0.30127.20M136.23M
2026-02-190.030.03129.69M144.55M
2025-10-300.28-0.31164.86M146.98M
2025-08-06-0.14-0.28114.45M99.55M
2025-05-01-0.47-0.5581.73M88.80M
2025-02-20-0.73-0.5874.79M72.38M
2024-10-31-0.70-0.7062.90M71.44M
2024-08-01-0.90-0.8754.12M57.77M
2024-05-06-1.76-0.9841.37M42.85M
2024-02-15-1.16-1.2745.06M41.51M
2023-11-07-1.17-1.0937.09M117.31M
2023-08-03-1.13-1.1659.70M53.71M
2023-05-04-1.27-1.1856.99M50.61M
2023-02-23-1.03-1.0455.87M53.01M
2022-10-27-1.09-0.9753.50M54.12M
2022-08-04-1.05-0.9454.17M49.63M
2022-05-05-1.20-0.8548.49M52.19M
2022-02-24-0.84-0.7257.25M57.80M
2021-10-28-0.59-0.7268.22M52.64M
2021-07-29-0.64-0.7354.62M54.62M
2021-05-06-0.96-0.5647.41M36.10M
2021-03-01-2.37-0.4350.98M—
2020-11-05-0.44-0.5251.14M—
2020-07-30-0.58-0.5648.43M—
2020-05-110.02-0.6747.77M—
2020-02-24-0.70-0.6446.69M—
2019-10-30-0.55-1.0544.37M—
2019-08-06-0.92-0.6444.71M—
2019-05-07-0.81-0.5739.57M—
2019-02-26-0.18-0.4843.77M—
2018-11-01-0.92-0.4540.71M—
2018-07-26-0.56-0.3541.34M—
2018-05-01-0.46-0.4538.43M—
2018-02-27-0.45-0.1942.18M—
2017-11-07-0.46-0.2540.34M—
2017-08-09-0.34-0.2138.80M—
2017-05-04-0.29-0.2633.62M—
2017-03-01-0.23-0.2637.33M—

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-10-15Dube Eric MBuy200.00K$8.931.79M
2026-10-15Dube Eric MSell128.06K$52.976.78M
2026-10-15Dube Eric MSell37.27K$54.202.02M
2026-10-15Dube Eric MBuy43.73K$26.881.18M
2026-10-15Dube Eric MSell78.40K$55.024.31M
2026-10-15Dube Eric MSell43.73K$26.881.18M
2026-10-15Dube Eric MSell200.00K$8.931.79M
2026-09-17Heerma PeterBuy8.28K$22.40185.52K
2026-09-17Heerma PeterSell8.28K$65.07538.92K
2026-09-17Heerma PeterSell8.28K$22.40185.52K
2026-09-17Dube Eric MBuy108.49K$23.342.53M
2026-09-17Dube Eric MSell101.69K$64.596.57M
2026-09-17Dube Eric MSell6.80K$64.95441.80K
2026-09-17Dube Eric MSell108.49K$23.342.53M
2026-09-16ROTE WILLIAM E.Buy57.50K$26.881.55M
2026-09-16ROTE WILLIAM E.Buy55.00K$15.46850.30K
2026-09-16ROTE WILLIAM E.Sell65.10K$63.124.11M
2026-09-16ROTE WILLIAM E.Buy350$17.966.29K
2026-09-16ROTE WILLIAM E.Sell47.75K$63.613.04M
2026-09-16ROTE WILLIAM E.Sell57.50K$26.881.55M
2026-09-16ROTE WILLIAM E.Sell55.00K$15.46850.30K
2026-09-16ROTE WILLIAM E.Sell350$17.966.29K
2026-09-16Heerma PeterBuy17.72K$26.88476.23K
2026-09-16Heerma PeterBuy55.00K$15.46850.30K
2026-09-16Heerma PeterBuy100.00K$11.251.12M
2026-09-16Heerma PeterSell93.60K$63.255.92M
2026-09-16Heerma PeterSell79.11K$63.655.04M
2026-09-16Heerma PeterSell17.72K$26.88476.23K
2026-09-16Heerma PeterSell100.00K$11.251.12M
2026-09-16Heerma PeterSell55.00K$15.46850.30K
2026-09-16Dube Eric MBuy195.84K$23.344.57M
2026-09-16Dube Eric MSell99.72K$63.266.31M
2026-09-16Dube Eric MSell96.12K$63.646.12M
2026-09-16Dube Eric MSell195.84K$23.344.57M
2026-09-15ROTE WILLIAM E.Buy39.65K$17.96712.11K
2026-09-15ROTE WILLIAM E.Buy39.00K$25.25984.75K
2026-09-15ROTE WILLIAM E.Sell63.91K$61.993.96M
2026-09-15ROTE WILLIAM E.Sell29.02K$62.661.82M
2026-09-15ROTE WILLIAM E.Sell3.00K$63.65190.95K
2026-09-15ROTE WILLIAM E.Sell270$65.3117.63K
2026-09-15ROTE WILLIAM E.Sell39.65K$17.96712.11K
2026-09-15ROTE WILLIAM E.Sell39.00K$25.25984.75K
2026-09-15Heerma PeterBuy36.53K$8.93326.18K
2026-09-15Heerma PeterBuy1.38K$22.4030.93K
2026-09-15Heerma PeterBuy39.28K$26.881.06M
2026-09-15Heerma PeterSell71.94K$62.054.46M
2026-09-15Heerma PeterSell27.42K$62.591.72M
2026-09-15Heerma PeterSell1.40K$63.6589.11K
2026-09-15Heerma PeterSell1.43K$65.3193.46K
2026-09-15Heerma PeterSell1.38K$22.4030.93K
2026-09-15Heerma PeterSell36.53K$8.93326.18K
2026-09-15Heerma PeterSell39.28K$26.881.06M
2026-09-15Inrig JulaBuy32.40K$8.93289.29K
2026-09-15Inrig JulaSell25.39K$62.021.57M
2026-09-15Inrig JulaSell17.28K$62.621.08M
2026-09-15Inrig JulaSell1.60K$63.69101.90K
2026-09-15Inrig JulaSell400$65.3126.12K
2026-09-15Inrig JulaSell32.40K$8.93289.29K
2026-09-15REED ELIZABETH EBuy37.50K$15.46579.75K
2026-09-15REED ELIZABETH ESell21.93K$62.031.36M
2026-09-15REED ELIZABETH ESell13.87K$62.63868.96K
2026-09-15REED ELIZABETH ESell1.40K$63.6989.17K
2026-09-15REED ELIZABETH ESell300$65.3119.59K
2026-09-15REED ELIZABETH ESell37.50K$15.46579.75K
2026-09-15Dube Eric MBuy95.67K$23.342.23M
2026-09-15Dube Eric MSell63.50K$61.993.94M
2026-09-15Dube Eric MSell28.80K$62.661.80M
2026-09-15Dube Eric MSell3.10K$63.64197.42K
2026-09-15Dube Eric MSell270$65.3117.63K
2026-09-15Dube Eric MSell95.67K$23.342.23M
2026-09-15Cline Christopher R.Buy20.00K$17.44348.80K
2026-09-15Cline Christopher R.Sell27.47K$62.001.70M
2026-09-15Cline Christopher R.Sell20.73K$62.611.30M
2026-09-15Cline Christopher R.Sell1.90K$63.69121.00K
2026-09-15Cline Christopher R.Sell400$65.3126.12K
2026-09-15Cline Christopher R.Sell20.00K$17.44348.80K
2026-09-15Calvin SandraBuy1.62K$20.4633.25K
2026-09-15Calvin SandraBuy1.25K$22.4028.00K
2026-09-15Calvin SandraBuy2.50K$27.5068.75K
2026-09-15Calvin SandraSell4.28K$62.13265.63K
2026-09-15Calvin SandraSell800$62.8550.28K
2026-09-15Calvin SandraSell300$63.6619.10K
2026-09-15Calvin SandraSell1.62K$20.4633.25K
2026-09-15Calvin SandraSell1.25K$22.4028.00K
2026-09-15Calvin SandraSell2.50K$27.5068.75K
2026-09-10Meckler Jeffrey ABuy10.00K$26.52265.20K
2026-09-10Meckler Jeffrey ASell1.70K$65.39111.17K
2026-09-10Meckler Jeffrey ASell1.20K$66.1579.38K
2026-09-10Meckler Jeffrey ABuy10.00K$17.44174.40K
2026-09-10Meckler Jeffrey ASell14.00K$67.46944.49K
2026-09-10Meckler Jeffrey ASell3.10K$68.09211.07K
2026-09-10Meckler Jeffrey ASell10.00K$17.44174.40K
2026-09-10Meckler Jeffrey ASell10.00K$26.52265.20K
2026-09-02Cline Christopher R.Sell642$66.3742.61K
2026-08-18LYONS GARY ABuy5.00K$17.4487.20K
2026-08-18LYONS GARY ASell4.10K$63.27259.39K
2026-08-18LYONS GARY ASell900$63.8657.47K
2026-08-18LYONS GARY ASell5.00K$17.4487.20K
2026-08-17LYONS GARY ASell1.90K$62.53118.80K
2026-08-17LYONS GARY ASell2.60K$63.50165.10K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 332, holders +52 vs prior quarter. Ownership 113.51%.

HolderSharesChangeChange %Value
JUPITER TOPCO LLC11.32M11.32MNew643.30M
BLACKROCK, INC.8.02M228.63K+2.93%455.65M
FMR LLC7.10M-3.87M-35.30%403.16M
BANK OF AMERICA CORP /DE/4.57M3.22M+239.63%259.53M
STATE STREET CORP4.26M-703.76K-14.19%241.80M
VANGUARD CAPITAL MANAGEMENT LLC4.11M62.88K+1.55%233.41M
PERCEPTIVE ADVISORS LLC3.75M-389.98K-9.41%213.18M
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.2.81M-458.00K-14.00%159.78M
ADAGE CAPITAL PARTNERS GP, L.L.C.2.57M1.59M+162.98%145.97M
GEODE CAPITAL MANAGEMENT, LLC2.37M2.33K+0.10%134.77M
ROCK SPRINGS CAPITAL MANAGEMENT LP2.18M701.12K+47.44%123.79M
KYNAM CAPITAL MANAGEMENT, LP2.00M1.20M+150.00%113.62M
STEPHENS INVESTMENT MANAGEMENT GROUP LLC1.88M76.84K+4.27%106.54M
RENAISSANCE TECHNOLOGIES LLC1.83M-133.70K-6.80%104.14M
EMERALD ADVISERS, LLC1.60M43.69K+2.81%90.95M
ARMISTICE CAPITAL, LLC1.57M-3.32M-67.89%89.34M
TWO SIGMA INVESTMENTS, LP1.57M57.40K+3.81%88.94M
VANGUARD PORTFOLIO MANAGEMENT LLC1.54M-167.52K-9.80%87.58M
GOLDMAN SACHS GROUP INC1.54M-184.40K-10.72%87.22M
WELLINGTON MANAGEMENT GROUP LLP1.53M510.81K+49.97%87.09M
QUBE RESEARCH & TECHNOLOGIES LTD1.44M774.07K+115.68%81.99M
D. E. SHAW & CO., INC.1.44M603.92K+72.19%81.83M
DRIEHAUS CAPITAL MANAGEMENT LLC1.44M156.62K+12.21%81.76M
MARSHALL WACE, LLP1.33M1.15M+646.74%75.74M
PRICE T ROWE ASSOCIATES INC /MD/1.32M913.81K+225.74%74.91M

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Travere Therapeutics (TVTX) Stock Insights

TVTX$50.45-0.43 -0.85%

$4.76B

Market Cap

-111.29

P/E

16.34

Forward P/E

54

Score

Price History